RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancerBoth Roche and Novartis are cognizant ONCY's potential as a late-stage clinical development company, particularly with pelareorep's ability to synergize with other biologics like immune checkpoint inhibitors, bispecifics, ADCs, CAR-T therapies, as well as small molecules like CDK4, CDK6, and PARP inhibitors, as just several examples.
Now that ONCY has the ACCELERATED APPROVAL and Breakthrough Therapy Designation open, the early approval of pelareorep has exponentially increased.